[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100495577":3},{"organization":4,"armGroups":7,"interventions":13,"overallOfficials":18,"centralContacts":22,"locations":31,"responsibleParty":47,"collaborators":10,"id":49,"slug":50,"hasResults":51,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":10,"eligibilityCriteria":55,"healthyVolunteers":51,"sex":56,"minAge":57,"maxAge":10,"enrollmentInfo":58,"targetDuration":61,"studyType":62,"phases":10,"briefSummary":63,"conditions":64,"keywords":68,"overallStatus":33,"whyStopped":10,"lastUpdateSubmitDate":74,"lastUpdatePostDateStruct":75,"startDateStruct":78,"completionDateStruct":80,"leadSponsor":82,"locationsCount":83},{"fullName":5,"class":6},"Memorial Sloan Kettering Cancer Center","OTHER",[8],{"label":9,"type":10,"description":10,"interventionNames":11},"Participants with refractory thyroid cancer patients",null,[12],"Other: Surveillance Visit",[14],{"type":6,"name":15,"description":16,"armGroupLabels":17,"otherNames":10},"Surveillance Visit","Follow-up visits will be carried out at intervals per usual clinical practice. Tolerance of medication and adverse events will be recorded in every visit.",[9],[19],{"name":20,"affiliation":5,"role":21},"Laura Boucai, MD","PRINCIPAL_INVESTIGATOR",[23,27],{"name":20,"role":24,"phone":25,"phoneExt":10,"email":26},"CONTACT","646-608-3906","boucail@mskcc.org",{"name":28,"role":24,"phone":29,"phoneExt":10,"email":30},"Alan Ho, MD, PhD","646-608-3774","hoa@mskcc.org",[32],{"facility":5,"status":33,"city":34,"state":34,"zip":35,"country":36,"countryCode":37,"cosmosGeoPoint":38,"geoPoint":43,"contacts":44},"RECRUITING","New York","10065","United States","US",{"type":39,"coordinates":40},"Point",[41,42],-74.00597,40.71427,{"lat":42,"lon":41},[45],{"name":46,"role":24,"phone":25,"phoneExt":10,"email":10},"Laura Boucai, PhD",{"type":48,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100495577","a-study-to-collect-information-about-the-use-of-redifferentiating-medications-as-a-standard-treatment-for-thyroid-cancer-100495577",false,"NCT05733013","A Study to Collect Information About the Use of Redifferentiating Medications as a Standard Treatment for Thyroid Cancer","Outcomes of Patients With Thyroid Carcinoma Treated With Redifferentiating Agents as Part of Routine Clinical Care: A Prospective Data Collection Study","Inclusion Criteria:\n\n* Patients ≥ 18 years old at time of consent\n\nInclusion Criteria:\n\n* Patients diagnosed with RAI refractory thyroid cancer or unlikely to respond to RAI.\n* Patients who will receive redifferentiation agents prior to planned diagnostic and\u002For therapeutic use of radioactive iodine as part of routine clinical care.\n* Patients who have never received redifferentiation agents outside of a clinical trial or have received redifferentiation agents in the context of a clinical trial will be enrolled after the clinical team has decided to proceed with a redifferentiation agent as part of routine clinical care prior to diagnostic and\u002For therapeutic radioactive iodine administration.\n* Patients previously treated with redifferentiation agents as part of clinical care prior to diagnostic and\u002For therapeutic radioactive iodine administration who are willing to provide retrospectively collected data surrounding the time of the previous treatment and will provide prospective data from the time of consent.\n\nExclusion Criteria:\n\n* RAI refractory thyroid cancer patients that will receive redifferentiation agents prior to diagnostic and\u002For therapeutic use of radioactive iodine as part of a prospective clinical trial.","ALL","18 Years",{"count":59,"type":60},100,"ESTIMATED","100 Years","OBSERVATIONAL","The purpose of this study to learn more about the use of redifferentiating medications as a standard treatment for radioactive iodine\u002FRAI-refractory thyroid cancer. This study is a registry study.",[65,66,67],"Thyroid Cancer","Thyroid","Refractory Thyroid Cancer",[69,70,71,67,72,73,5],"RAI refractory thyroid cancer","thyroid cancer","thyroid","Radio-iodine refractory thyroid cancer","22-320","2026-04-22",{"date":76,"type":77},"2026-04-27","ACTUAL",{"date":79,"type":77},"2023-02-07",{"date":81,"type":60},"2028-02-07",{"name":5,"class":6},1]